About ReveraGen
ReveraGen is a Healthcare company based in Rockville (United States) founded in 2008 by Kanneboyina Nagaraju. Steroids for Duchenne muscular dystrophy treatment are developed. Its chief executive, as recorded, is Eric Hoffman. ReveraGen offers products and services including Vamorolone. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its legal entity is ReveraGen BioPharma, Inc. Its competitors include Alnylam, Ultragenyx and BioMarin Pharmaceutical; 3 of its 3 listed competitors have raised funding.
Company details
ReveraGen was founded in 2008 in Rockville, United States, as a drug development company focused on neuromuscular diseases. Proprietary therapeutic products, including the lead candidate Vamorolonea steroidal anti-inflammatoryare discovered and developed for conditions such as Duchenne muscular dystrophy. Operations center on advancing treatments through clinical stages, with emphasis on innovative steroid formulations for patient care in the biotechnology sector.
- Headquarters Rockville, United States
- Founders Kanneboyina Nagaraju
- SectorsHealthcare
- Website reveragen.com
- Social X
- Legal Name Reveragen Biopharma, Inc.
- Latest Funding Round$1.2M (USD), Grant
Sep 2021
- InvestorsNIH
& 9 more
Products & Services of ReveraGen
ReveraGen offers a comprehensive portfolio of products and services, including Vamorolone.
Drug designed to treat Duchenne Muscular Dystrophy with improved safety.
Funding Insights of ReveraGen
- Total Rounds 19
- Last Round Grant — $1.2M
- First Round $375,244
(Sep 2010)
- Investors Count 10
Latest 10 of 19 funding rounds of ReveraGen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $1.2M | Grant | – | – | |
| Sep 2021 | $1.2M | Grant | – | – | |
| Nov 2020 | $3.3M | Grant | – | – | |
| Aug 2019 | $286,131 | Grant | – | – | |
| Jul 2018 | $224,998 | Grant | – | – | |
| Jun 2018 | $225,000 | Grant | – | – | |
| Jun 2018 | $178,041 | Grant | – | – | |
| Feb 2018 | $800,000 | Debt – Conventional | – | – | – |
| Apr 2016 | $253,802 | Grant | – | – | |
| Mar 2016 | $3M | Grant | – | – |
10 investors in total: 10 institutional.
Investors in ReveraGen
ReveraGen has secured backing from 10 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
The U.S. Food and Drug Administration is tasked with regulating food, drugs, and medical products. | fda.gov | United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Duchenne UK is focused on funding research and support for Duchenne muscular dystrophy. | duchenneuk.org | Hammersmith, United Kingdom | ||
Research on neurological disorders and stroke is conducted and funded. | ninds.nih.gov | Bethesda, United States | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
| ryansquest.org | ||||
A community foundation dedicated to advancing cures for neuromuscular diseases. | 1950 | mda.org | Chicago, United States | |
Joining Jack is focused on fundraising for Duchenne research. | 2012 | joiningjack.org | Wigan, United Kingdom | |
Funds research collaborations and treatments for Duchenne muscular dystrophy worldwide. | 2007 | duchenne.org.uk | London, United Kingdom |
Investor details for ReveraGen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of ReveraGen
5 people are tracked at ReveraGen (4 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Kanneboyina Nagaraju | Co-Founder | Leadership |
Eric Hoffman | CEO | Leadership |
Jesse Damsker | Chief Operating Officer | Leadership |
Johannes Van Den Anker | Chief Medical Officer | Leadership |
Elizabeth Albrecht Singer | Board Director | Board & advisors |
Complete people profiles for ReveraGen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of ReveraGen
3 dated milestones of ReveraGen across 13 years, from founding to its latest funding, stage changes and deals.
- Founded ReveraGen is founded.
- Funding First funding round of $375K.
- Funding Latest funding round, Grant, of $1.2M.
Competitors of ReveraGen
ReveraGen has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and BioMarin Pharmaceutical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| biomarin.com | 1997 | San Rafael, United States | $37.5M | 2,124 | Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical. |
Detailed competitors of ReveraGen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of ReveraGen
The website of ReveraGen (reveragen.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 11.6% vs previous month
Top companies in Rare Diseases
3 companies that operate in the same segment as ReveraGen (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Reveragen
Complete news archive for ReveraGen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ReveraGen
ReveraGen was founded in 2008 and raised its 1st funding round 2 years after it was founded.
ReveraGen is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Eric Hoffman is the CEO of ReveraGen, as recorded in our data.
ReveraGen was founded in 2008 in Rockville, United States, as a drug development company focused on neuromuscular diseases. Proprietary therapeutic products, including the lead candidate Vamorolonea steroidal anti-inflammatoryare discovered and developed for conditions such as Duchenne muscular dystrophy. Operations center on advancing treatments through clinical stages, with emphasis on innovative steroid formulations for patient care in the biotechnology sector.
ReveraGen's top competitors include Alnylam, BioMarin Pharmaceutical and Ultragenyx.
ReveraGen offers Vamorolone.
ReveraGen has 10 investors. Key investors include NIH, HHS, European Union, U.S. Food and Drug Administration, and Duchenne UK.
ReveraGen operates through Reveragen Biopharma, Inc..